HoneyNaps has taken a significant step in enhancing its capabilities in clinical trial analytics by becoming a registered Contract Research Organization (CRO) with the Korea National Enterprise for Clinical Trials (KoNECT). This registration allows the company to offer advanced AI-powered sleep data analysis services, catering to the growing needs of the global pharmaceutical, medical device, and digital health sectors.
The launch of SOMNUM Clinical, HoneyNaps' AI-driven analytics service, marks a pivotal development. This platform utilizes the SOMNUM AI technology, which has received FDA clearances, to automate the analysis of polysomnography data. By efficiently assessing key sleep metrics, including sleep stages and apnea-hypopnea index, the service aims to streamline the traditionally labor-intensive processes of sleep-related clinical trials. The automation can reduce analysis time by over 90%, thus enhancing overall trial efficiency.
As the global clinical sleep health market is projected to grow significantly, reaching an estimated USD 36.9 billion by 2034, HoneyNaps is well-positioned to leverage its extensive experience from studies involving over 10,000 participants. The company’s capabilities allow it to provide standardized and reproducible analyses across multiple sites, addressing a critical need for objective data in sleep medicine and related therapeutic areas.
Sean Ha, President of HoneyNaps USA, emphasized the increasing importance of sleep as a digital biomarker across various health domains. He stated that the company aims to expand its focus beyond sleep disorders to include trials for pharmaceuticals and digital therapeutics. This strategic move positions HoneyNaps as a potential leader in AI-driven clinical trial analytics, driven by the evolving landscape of digital health solutions.